Primary Progressive Multiple Sclerosis (PPMS) Treatment Global Market Report 2025

Description

Primary progressive multiple sclerosis (PPMS) treatment encompasses medical and therapeutic strategies designed to manage and slow the progression of PPMS-a form of multiple sclerosis marked by a continuous decline in neurological function from the onset, without distinct relapses or remissions. These interventions aim to reduce disease activity, ease symptoms, preserve mobility, and enhance patients' quality of life.

The primary drug categories utilized in the management of primary progressive multiple sclerosis (PPMS) include monoclonal antibodies, immunosuppressants, corticosteroids, and various other drug types. Monoclonal antibodies (mAbs) are synthetically engineered proteins that specifically bind to antigens on affected cells, serving diagnostic or therapeutic functions. These medications are delivered through different routes such as oral, intravenous, and others, and are made available via hospital pharmacies, retail pharmacies, online pharmacies, and additional distribution channels.

The primary progressive multiple sclerosis (PPMS) treatment market size has grown rapidly in recent years. It will grow from $1.02 billion in 2024 to $1.16 billion in 2025 at a compound annual growth rate (CAGR) of 13.7%. Growth during the historic period was supported by the increasing incidence of PPMS among older adults, enhanced awareness and knowledge of the condition among patients and medical professionals, higher R&D investments targeting PPMS therapies, greater use of disease-modifying treatments, and amplified governmental support and funding for emerging treatment options.

The primary progressive multiple sclerosis (PPMS) treatment market size is expected to see rapid growth in the next few years. It will grow to $1.92 billion in 2029 at a compound annual growth rate (CAGR) of 13.5%. This anticipated growth will be driven by the rising number of clinical trials exploring novel PPMS therapies, progress in diagnostic methods, a growing preference for precision and targeted medicine, improvements in healthcare infrastructure, and stronger collaboration and partnerships between pharmaceutical firms. Key trends expected during the forecast period include innovation in disease-modifying therapies aimed at halting PPMS progression, the application of biomarker studies for personalized treatment, enhanced imaging technologies such as MRI, advancements in neuroprotection and remyelination drug development, and breakthroughs in genetic and molecular patient profiling for more accurate treatment planning.

The growing demand for effective treatments is expected to propel the growth of the primary progressive multiple sclerosis (PPMS) treatment market going forward. Effective treatments are medical interventions that reduce symptoms, improve patient outcomes, or cure a disease or condition. This demand is primarily driven by the rising prevalence of chronic and complex health conditions, which require long-term management and advanced therapeutic interventions to improve patient outcomes and quality of life. These treatments help slow the progression of primary progressive multiple sclerosis (PPMS) by targeting inflammation and preserving neurological function, thereby improving long-term quality of life, reducing disability accumulation, and enhancing patients' ability to manage daily activities with greater independence and stability. For instance, in January 2024, according to the American Society of Gene & Cell Therapy, a US-based organization for gene and cell therapy, the number of gene therapies in Phase III clinical trials reached 33 Phase III gene therapy trials in 2023, an increase of 10% compared to 2022, representing the first quarterly increase since Q3 2022. Therefore, the growing demand for effective treatments drives the growth of the primary progressive multiple sclerosis (PPMS) treatment market.

Major companies operating in the primary progressive multiple sclerosis (PPMS) treatment market are focusing on developing innovative formulations such as monoclonal antibody drugs to enhance the treatment of multiple sclerosis. A monoclonal antibody drug helps in multiple sclerosis by targeting specific immune cells or proteins that cause inflammation and damage to the nervous system, reducing disease activity and slowing the progression of symptoms. For instance, in February 2024, Roche Pharma India, an India-based pharmaceutical company, launched Ocrevus (ocrelizumab), a monoclonal antibody drug, to treat multiple sclerosis (MS) in India. Ocrevus is notable for being the first and only approved disease-modifying therapy (DMT) for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) in the country. The drug works by targeting CD20-positive B cells, a type of immune cell involved in the abnormal immune response seen in MS. It is administered as a twice-yearly intravenous infusion for only two hours, offering patients a more convenient and effective treatment option.

In March 2024, Viatris Inc., a US-based healthcare company focused on providing access to medicines, partnered with Mapi Pharma Ltd. to advance the development and commercialization of GA Depot 40 mg for multiple sclerosis treatment. Through this partnership, Viatris supports the regulatory and commercial pathway for GA Depot, a long-acting injectable therapy to improve treatment adherence and address unmet medical needs in managing multiple sclerosis. Mapi Pharma Ltd. is an Israel-based pharmaceutical company specializing in depot technologies and sustained-release formulations for central nervous system disorders, including multiple sclerosis.

Major players in the primary progressive multiple sclerosis (ppms) treatment market are F. Hoffmann-La Roche Ltd., Bayer HealthCare Pharmaceuticals Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Acorda Therapeutics Inc., Apitope International N.V., Atara Biotherapeutics Inc., Kyverna Therapeutics Inc., Clene Inc., Mapi Pharma Ltd., Abata Therapeutics Inc., MediciNova Inc., MedDay Pharmaceuticals SAS, AB Science S.A., Immunic AG, Brainstorm Cell Therapeutics Inc.

North America was the largest region in the primary progressive multiple sclerosis (PPMS) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in primary progressive multiple sclerosis (PPMS) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the primary progressive multiple sclerosis (PPMS) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary progressive multiple sclerosis (PPMS) treatment market consists of sales of ocrelizumab (ocrevus), mitoxantrone, baclofen, modafinil and oxybutynin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Primary Progressive Multiple Sclerosis (PPMS) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on primary progressive multiple sclerosis (ppms) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for primary progressive multiple sclerosis (ppms) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The primary progressive multiple sclerosis (ppms) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Type: Monoclonal Antibodies; Immunosuppressants; Corticosteroids; Other Drug Types
2) By Route Of Administration: Oral; Intravenous; Other Route Of Administrations
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
Subsegments:
1) By Monoclonal Antibodies: Ocrelizumab; Rituximab; Ofatumumab; Ublituximab
2) By Immunosuppressants: Methotrexate; Azathioprine; Mycophenolate Mofetil; Cyclophosphamide
3) By Corticosteroids: Methylprednisolone; Prednisone; Dexamethasone; Hydrocortisone
4) By Other Drug Types: Biotin; Ibudilast; Laquinimod; Idebenone
Companies Mentioned: F. Hoffmann-La Roche Ltd.; Bayer HealthCare Pharmaceuticals Inc.; Novartis AG; Sanofi S.A.; Bristol-Myers Squibb Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r36038

1. Executive Summary

2. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Characteristics

3. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Trends And Strategies

4. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Growth Analysis And Strategic Analysis Framework

5.1. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Growth Rate Analysis
5.4. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Total Addressable Market (TAM)

6. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Segmentation

6.1. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies
Immunosuppressants
Corticosteroids
Other Drug Types
6.2. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Intravenous
Other Route Of Administrations
6.3. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Distribution Channels
6.4. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ocrelizumab
Rituximab
Ofatumumab
Ublituximab
6.5. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Sub-Segmentation Of Immunosuppressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Methotrexate
Azathioprine
Mycophenolate Mofetil
Cyclophosphamide
6.6. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Methylprednisolone
Prednisone
Dexamethasone
Hydrocortisone
6.7. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Biotin
Ibudilast
Laquinimod
Idebenone

7. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Regional And Country Analysis

7.1. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

8.1. Asia-Pacific Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

9.1. China Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
9.2. China Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

10.1. India Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

11.1. Japan Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
11.2. Japan Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

12.1. Australia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

13.1. Indonesia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

14.1. South Korea Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
14.2. South Korea Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

15.1. Western Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
15.2. Western Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

16.1. UK Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

17.1. Germany Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

18.1. France Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

19.1. Italy Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

20.1. Spain Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

21.1. Eastern Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
21.2. Eastern Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

22.1. Russia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

23.1. North America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
23.2. North America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

24.1. USA Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
24.2. USA Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

25.1. Canada Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
25.2. Canada Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

26.1. South America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
26.2. South America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

27.1. Brazil Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

28.1. Middle East Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
28.2. Middle East Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

29.1. Africa Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
29.2. Africa Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Competitive Landscape And Company Profiles

30.1. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Competitive Landscape
30.2. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Bayer HealthCare Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Other Major And Innovative Companies

31.1. Amgen Inc.
31.2. Teva Pharmaceutical Industries Ltd.
31.3. Biogen Inc.
31.4. Acorda Therapeutics Inc.
31.5. Apitope International N.V.
31.6. Atara Biotherapeutics Inc.
31.7. Kyverna Therapeutics Inc.
31.8. Clene Inc.
31.9. Mapi Pharma Ltd.
31.10. Abata Therapeutics Inc.
31.11. MediciNova Inc.
31.12. MedDay Pharmaceuticals SAS
31.13. AB Science S.A.
31.14. Immunic AG
31.15. Brainstorm Cell Therapeutics Inc.

32. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

34. Recent Developments In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

35. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market High Potential Countries, Segments and Strategies

35.1 Primary Progressive Multiple Sclerosis (PPMS) Treatment Market In 2029 - Countries Offering Most New Opportunities
35.2 Primary Progressive Multiple Sclerosis (PPMS) Treatment Market In 2029 - Segments Offering Most New Opportunities
35.3 Primary Progressive Multiple Sclerosis (PPMS) Treatment Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer